TrialsgramBetaRCTs are beautiful
AHA Scientific Sessions 2026Präsentiert Mo., 9. Nov. · 08:45 GMT-6LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk ReductionAlle Studien (Late-Breaking Science) →

SYNCHRONIZE-CVOT

2026

SYNCHRONIZE-CVOT: Cardiovascular Safety Study With Survodutide in Participants With Overweight or Obesity

In adults with obesity or overweight at increased cardiovascular risk, survodutide was non-inferior to placebo for a five-component composite of major adverse cardiovascular events.

Ergebnis

Wirksamkeit: First of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation or heart failure eventHR 0,89 (95%-KI 0,67-1,18) · P < 0,0001

Unter 1 spricht für survodutide, über 1 für placebo.

Außerdem berichtet: Using the treatment-regimen estimand). 3P-MACE (cardiovascular death, non-fatal stroke or non-fatal myocardial infarction): HR 0.84 (95% CI 0.60-1.18; p<0.0001 for non-inferiority). At 72 weeks (supplementary estimand), systolic blood pressure fell by up to 6.68 mmHg vs 1.76 mmHg with placebo (P= 0.0001), waist circumference by up to 11.96 cm vs 2.74 cm, and body weight by up to 13.7% vs 2.0%. Treatment discontinuation due to gastrointestinal adverse events was 19.3% and 20.8% with survodutide vs 1.9% with placebo.

Originalpublikation
Unterthema
Obesity pharmacotherapy
Design
Phase 3, double-blind, placebo-controlled, event-driven cardiovascular safety trial (Boehringer Ingelheim; 540 sites) of subcutaneous survodutide 3.6 mg or 6.0 mg versus placebo, testing non-inferiority
Eingeschlossen
5.530 Patienten
Quelle
Bozkurt B. Presented at AHA Scientific Sessions 2026, 9 November. Boehringer Ingelheim press release, 9 November 2026. Published in The Lancet.doi 10.1016/s0140-6736(26)02140-9

Diskussion & Kritik

This event-driven trial shows that survodutide did not increase the risk of a five-component cardiovascular composite compared with placebo, meeting its non-inferiority margin. The confidence intervals for both 5P-MACE and 3P-MACE cross 1, so a cardiovascular benefit is not shown. The blood pressure, waist and weight figures are the best arm under a supplementary estimand, and about one in five participants on survodutide stopped treatment because of gastrointestinal adverse events. The sponsor's release gives no event counts per arm, no follow-up duration and no figures for hs-CRP or triglycerides.